Oncotarget

Research Papers:

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Milan Radovich, Patrick J. Kiel, Stacy M. Nance, Erin E. Niland, Megan E. Parsley, Meagan E. Ferguson, Guanglong Jiang, Natraj R. Ammakkanavar, Lawrence H. Einhorn, Liang Cheng, Mehdi Nassiri, Darrell D. Davidson, Daniel A. Rushing, Patrick J. Loehrer, Roberto Pili, Nasser Hanna, J. Thomas Callaghan, Todd C. Skaar, Paul R. Helft, Safi Shahda, Bert H. O’Neil & Bryan P. Schneider _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:56491-56500. https://doi.org/10.18632/oncotarget.10606

Metrics: PDF 1260 views  |   HTML 1908 views  |   ?  


Abstract

Milan Radovich1,2,*, Patrick J. Kiel1,2,*, Stacy M. Nance1, Erin E. Niland1, Megan E. Parsley1, Meagan E. Ferguson1, Guanglong Jiang2, Natraj R. Ammakkanavar2, Lawrence H. Einhorn2, Liang Cheng2, Mehdi Nassiri2, Darrell D. Davidson2, Daniel A. Rushing2, Patrick J. Loehrer2, Roberto Pili2, Nasser Hanna2, J. Thomas Callaghan2, Todd C. Skaar2, Paul R. Helft2, Safi Shahda2, Bert H. O’Neil2 and Bryan P. Schneider1,2

1 Indiana University Health Precision Genomics Program, Indianapolis, IN, USA

2 Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA

* These authors have contributed equally to this work

Correspondence to:

Bryan P. Schneider, email:

Keywords: precision medicine, personalized medicine, genomics, next-generation sequencing

Received: June 07, 2016 Accepted: June 09, 2016 Published: July 15, 2016

Abstract

Patients and Methods: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry for actionable targets. A multi-disciplinary tumor board reviewed all results. For each patient, the ratio of progression-free survival (PFS) of the genomically guided line of therapy divided by the PFS of their prior line was calculated. Patients whose PFS ratio was ≥ 1.3 were deemed to have a meaningful improvement in PFS.

Results: From April 2014–October 2015, 168 patients were evaluated and 101 patients achieved adequate clinical follow-up for analysis. 19 of 44 (43.2%) patients treated with genomically guided therapy attained a PFS ratio ≥ 1.3 vs. 3 of 57 (5.3%) treated with non-genomically guided therapy (p < 0.0001). Similarly, overall PFS ratios (irrespective of cutoff) were higher for patients with genomically guided therapy vs non-genomically guided therapy (p = 0.05). Further, patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p = 0.005, H.R. = 0.55, 95% C.I.:0.37-0.84).

Conclusion: Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10606